<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Inc. pmcid: 7092853S0006-291X(19)32332-0 doi: 10.1016/j.bbrc.2019.12.012 : Article Cephalotaxine inhibits Zika" exact="infection" post="by impeding viral replication and stability LaiZheng-ZongabcHoYi-Jungde∗∗LuJeng-Weijengweilu@gmail.comf∗[a], [b], [c],"/>
 <result pre="doi: 10.1016/j.bbrc.2019.12.012 : Article Cephalotaxine inhibits Zika infection by impeding" exact="viral" post="replication and stability LaiZheng-ZongabcHoYi-Jungde∗∗LuJeng-Weijengweilu@gmail.comf∗[a], [b], [c], [d], [e], [f],"/>
 <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
 <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
 <result pre="reemerged as a serious public health problem around the world." exact="Syndromes" post="of infected people range from asymptomatic infections to severe"/>
 <result pre="around the world. Syndromes of infected people range from asymptomatic" exact="infections" post="to severe neurological disorders, such as Guillain-Barré syndrome and"/>
 <result pre="range from asymptomatic infections to severe neurological disorders, such as" exact="Guillain-Barré syndrome" post="and microcephaly. Screening anti-ZIKV drugs derived from Chinese medicinal"/>
 <result pre="from asymptomatic infections to severe neurological disorders, such as Guillain-Barré" exact="syndrome" post="and microcephaly. Screening anti-ZIKV drugs derived from Chinese medicinal"/>
 <result pre="underlie these effects involve virucidal activity and a decrease in" exact="viral" post="replication. Specifically, CET was found to decrease ZIKV RNA"/>
 <result pre="replication. Specifically, CET was found to decrease ZIKV RNA and" exact="viral" post="protein expression, inhibit ZIKV replication, and inhibit ZIKV mRNA/protein"/>
 <result pre="a new class of anti-Flavivirus medications. Highlights •CET against ZIKV" exact="infection" post="via inhibiting replication and stability. •CET was identified as"/>
 <result pre="a candidate compound for potential ZIKV treatment. Keywords Antiviral Cephalotaxine" exact="Viral" post="production Replication Dengue virus Zika virus 1 Introduction The"/>
 <result pre="for potential ZIKV treatment. Keywords Antiviral Cephalotaxine Viral production Replication" exact="Dengue" post="virus Zika virus 1 Introduction The Zika virus (ZIKV)"/>
 <result pre="genus and the Flaviviridae family (a family to which the" exact="Hepatitis" post="C virus (HCV], Dengue virus (DENV], West Nile virus"/>
 <result pre="family (a family to which the Hepatitis C virus (HCV]," exact="Dengue" post="virus (DENV], West Nile virus (WNV], Yellow fever virus"/>
 <result pre="C virus (HCV], Dengue virus (DENV], West Nile virus (WNV]," exact="Yellow fever" post="virus [YFV], and Japanese encephalitis virus [JEV] also belong.)"/>
 <result pre="(DENV], West Nile virus (WNV], Yellow fever virus [YFV], and" exact="Japanese encephalitis" post="virus [JEV] also belong.) ZIKV was first isolated from"/>
 <result pre="West Nile virus (WNV], Yellow fever virus [YFV], and Japanese" exact="encephalitis" post="virus [JEV] also belong.) ZIKV was first isolated from"/>
 <result pre="near the Zika Forest in Uganda in 1947 [1,2]. The" exact="viral" post="genome of ZIKV encodes a polyprotein which consists of"/>
 <result pre="NS4A, NS4 B, and NS5 [3]. In recent years, ZIKV" exact="infection" post="has become a serious and escalating threat to global"/>
 <result pre="in 2015 in at least 33 regions and countries in" exact="Central" post="and South America, such as Brazil, becoming an epidemic"/>
 <result pre="0.5 and 1.5 million people [[4], [5], [6], [7]]. ZIKV" exact="infection" post="has been associated with several neurological complications, such as"/>
 <result pre="infection has been associated with several neurological complications, such as" exact="Guillain-Barré syndrome" post="in adults and microcephaly in infants [8,9]. Prior to"/>
 <result pre="has been associated with several neurological complications, such as Guillain-Barré" exact="syndrome" post="in adults and microcephaly in infants [8,9]. Prior to"/>
 <result pre="several neurological complications, such as Guillain-Barré syndrome in adults and" exact="microcephaly" post="in infants [8,9]. Prior to the outbreak which affected"/>
 <result pre="[8,9]. Prior to the outbreak which affected Brazil and other" exact="Central" post="and South American countries, ZIKV infection was only considered"/>
 <result pre="the outbreak which affected Brazil and other Central and South" exact="American" post="countries, ZIKV infection was only considered to lead only"/>
 <result pre="affected Brazil and other Central and South American countries, ZIKV" exact="infection" post="was only considered to lead only to a mild"/>
 <result pre="such as fetal growth restrictions as well as neurological and" exact="ocular" post="abnormalities. In some cases, ZIKV during pregnancy can even"/>
 <result pre="perinatal death [10]. ZIKV is also known to cause a" exact="benign" post="febrile illness in approximately 18% of infected individuals. This"/>
 <result pre="to those of other arbovirus infections, including DENV and the" exact="chikungunya" post="virus (CHIKV). Specifically, these symptoms include fever, rash, joint"/>
 <result pre="vomiting and jaundice [11]. Other clinical symptoms typical of ZIKV" exact="infection" post="include fever, headaches, joint pain, conjunctivitis, and macular atrophy"/>
 <result pre="ZIKV infection include fever, headaches, joint pain, conjunctivitis, and macular" exact="atrophy" post="[12]. In February 2016, the World Health Organization (WHO)"/>
 <result pre="Emergency of International Concern (PHEIC) [13]. Strategies of fighting ZIKV" exact="infection" post="include the development of vaccines and the screening of"/>
 <result pre="screening of antiviral agents that inhibit different stages of the" exact="viral" post="life cycle [14]. Unfortunately, no approved antiviral ZIKV agents"/>
 <result pre="Cephalotaxus hainanensis [15]. CET has shown promising antiviral activities against" exact="hepatitis" post="B [16] and has also been found to have"/>
 <result pre="including some cancers [18]. HT inhibits CHIKV replication by down-regulating" exact="viral" post="protein expression, while HHT shows activity against HBV and"/>
 <result pre="In so doing, we demonstrated that CET (1) disrupts the" exact="viral" post="life cycle by preventing ZIKV from replicating and (2)"/>
 <result pre="(African green monkey kidney cells; ATCC® CRL-1586TM) and A549 (Human" exact="lung carcinoma" post="epithelial cells; ATCC® CCL-185™) cells, as these cells are"/>
 <result pre="green monkey kidney cells; ATCC® CRL-1586TM) and A549 (Human lung" exact="carcinoma" post="epithelial cells; ATCC® CCL-185™) cells, as these cells are"/>
 <result pre="monkey kidney cells; ATCC® CRL-1586TM) and A549 (Human lung carcinoma" exact="epithelial" post="cells; ATCC® CCL-185™) cells, as these cells are more"/>
 <result pre="a serial dilution of virus medium. Following a 2 h" exact="infection" post="period, the cells were overlaid with DMEM containing 1.5%"/>
 <result pre="methylcellulose and 2% FBS, and then incubated for two days." exact="Viral" post="fluorescence foci were visualized and counted using an inverted"/>
 <result pre="days. Viral fluorescence foci were visualized and counted using an" exact="inverted" post="fluorescence microscope (Olympus CKX41). 2.4 Virus reduction assay Confluent"/>
 <result pre="After another two-day incubation period, supernatants were harvested and the" exact="viral" post="titers contained therein were determined using IFA. Relative quantifications"/>
 <result pre="determined using quantitative reverse transcription PCR (qRT-PCR). 2.5 qRT-PCR The" exact="total" post="RNA of cells was extracted 24 or 48 h"/>
 <result pre="After a final PBS wash, cells were observed using an" exact="inverted" post="fluorescence microscope (Olympus CKX41) [23,24]. 2.7 Time of addition"/>
 <result pre="Time of addition assay To determine which stage of the" exact="viral" post="life cycle that CET acts upon, we compared its"/>
 <result pre="For the full-duration treatment group, CET was added throughout the" exact="infection" post="period. (2) For the co-treatment group, CET was added"/>
 <result pre="for 24 h, at which point the levels of intracellular" exact="viral" post="RNA were compared with those of a vehicle group"/>
 <result pre="vehicle group using qRT-PCR [22,23]. 2.8 Western blot analysis Intracellular" exact="viral" post="envelope protein levels were measured by Western blot. Briefly,"/>
 <result pre="and anti-β-actin (1:4000; Santa Cruz Biotechnology, Dallas, Texas, USA) as" exact="primary" post="antibodies as well as anti-mouse or anti-human horseradish peroxidase-conjugated"/>
 <result pre="as well as anti-mouse or anti-human horseradish peroxidase-conjugated antibodies as" exact="secondary" post="antibodies. Target proteins were detected using an ECL reagent,"/>
 <result pre="diluted in DMEM and added to the confluent Vero cells." exact="Viral" post="titers were determined by counting viral fluorescence foci using"/>
 <result pre="the confluent Vero cells. Viral titers were determined by counting" exact="viral" post="fluorescence foci using the previously described IFA method [23]."/>
 <result pre="indicated concentrations of CET for 48 h. Following this, dose-dependent" exact="viral" post="RNA reduction assays were performed using qRT-PCR to determine"/>
 <result pre="using qRT-PCR to determine whether CET was effective in inhibiting" exact="viral" post="replication [23]. 2.11 Statistical analysis Statistical analysis was performed"/>
 <result pre="significant [[22], [23], [24]]. 3 Results 3.1 CET inhibited ZIKV" exact="infection" post="Earlier research found that CET was able to inhibit"/>
 <result pre="Earlier research found that CET was able to inhibit HBV" exact="infection" post="[16]; however, the anti-viral effects of CET against other"/>
 <result pre="that CET from 20 to 100 μM significantly inhibited ZIKV" exact="infection" post="in a dose-dependent manner (Fig. 1 A, B, and"/>
 <result pre="(B–D) The anti-ZIKV ability of CET was verified by measuring" exact="viral" post="RNA levels, protein expression, and viral titers. (B) ZIKV"/>
 <result pre="was verified by measuring viral RNA levels, protein expression, and" exact="viral" post="titers. (B) ZIKV RNA levels were analyzed by qRT-PCR."/>
 <result pre="were employed. Results of qRT-PCR showed that CET inhibited ZIKV" exact="infection" post="in a dose-dependent manner (Fig. 2B). In particular, a"/>
 <result pre="Our data indicated that CET is able to inhibit ZIKV" exact="infection" post="by decreasing viral RNA, protein, and progeny yield. Therefore,"/>
 <result pre="that CET is able to inhibit ZIKV infection by decreasing" exact="viral" post="RNA, protein, and progeny yield. Therefore, to further investigate"/>
 <result pre="per well for 1 h) Following the end of the" exact="infection" post="period, cells were washed two times and the medium"/>
 <result pre="revealed that CET likely affects the late stage of ZIKV" exact="infection" post="(Fig. 3 A and B), which means that the"/>
 <result pre="further analysis. Results showed that administering CET after the initial" exact="infection" post="(i.e., the post-treatment group) suppressed viral RNA replication. In"/>
 <result pre="CET after the initial infection (i.e., the post-treatment group) suppressed" exact="viral" post="RNA replication. In particular, when cells in the post-treatment"/>
 <result pre="significantly reduced (Fig. 3C). FFU assays further revealed that the" exact="viral" post="yield decreased in the post-treatment group when cells were"/>
 <result pre="virus progeny production. The effects of administering CET after ZIKV" exact="infection" post="(i.e., the post-treatment group) as revealed by (C) qRT-PCR"/>
 <result pre="the potential to be used in the treatment of dengue" exact="virus infection." post="Fig. 4 Inhibition of CET activity in different serotypes"/>
 <result pre="infection. Specifically, results of IFA revealed that CET treatment reduced" exact="viral infection" post="in both Vero and A549 cells (Fig. 1). Researchers"/>
 <result pre="Specifically, results of IFA revealed that CET treatment reduced viral" exact="infection" post="in both Vero and A549 cells (Fig. 1). Researchers"/>
 <result pre="not cytotoxic and whereas they induced dose-dependent anti-HBV and anti-bovine" exact="viral" post="diarrhoea virus (BVDV) as a surrogate for HCV effects,"/>
 <result pre="cytotoxicity and does not affect cell viability (Fig. 2A). Moreover," exact="viral" post="RNA levels, protein expression levels, and viral titers (Fig."/>
 <result pre="(Fig. 2A). Moreover, viral RNA levels, protein expression levels, and" exact="viral" post="titers (Fig. 2B, C, and 2D) in CET-treated Vero"/>
 <result pre="antiviral activities are most likely due to cellular rather than" exact="viral" post="factors and that cellular factors are essential for viral"/>
 <result pre="than viral factors and that cellular factors are essential for" exact="viral" post="replication. CET esters have been shown to interfere with"/>
 <result pre="inhibiting large ribosomal subunits and subsequently down-regulating the translation of" exact="viral" post="proteins [19]. Similar to previous studies, results of our"/>
 <result pre="assay showed that CET affected the late stage of ZIKV" exact="infection" post="(Fig. 3A and B). We further sought to determine"/>
 <result pre="that received CET after ZIKV-infection), the decreases we observed in" exact="viral" post="replication and viral release were the same, which suggest"/>
 <result pre="after ZIKV-infection), the decreases we observed in viral replication and" exact="viral" post="release were the same, which suggest that the primary"/>
 <result pre="and viral release were the same, which suggest that the" exact="primary" post="mechanism by which CET inhibited ZIKV involved viral replication,"/>
 <result pre="that the primary mechanism by which CET inhibited ZIKV involved" exact="viral" post="replication, not virus release. However, the time of addition"/>
 <result pre="release. However, the time of addition assay showed that the" exact="viral" post="yield of the full-duration treatment group was lower than"/>
 <result pre="that the viral yield of the full-duration treatment group was" exact="lower" post="than that of the post-treatment group (by approximately 0.5"/>
 <result pre="3B). This finding suggests that not only can CET disrupt" exact="viral" post="replication, but it may also possess other anti-ZIKV activities."/>
 <result pre="of CET, the results of which confirmed that CET decreased" exact="viral" post="stability, thereby reducing viral yield (Fig. 3E). In summary,"/>
 <result pre="of which confirmed that CET decreased viral stability, thereby reducing" exact="viral" post="yield (Fig. 3E). In summary, our data indicate that"/>
 <result pre="our data indicate that CET is able to inhibit ZIKV" exact="infection" post="by affecting both viral replication and viral stability. Finally,"/>
 <result pre="CET is able to inhibit ZIKV infection by affecting both" exact="viral" post="replication and viral stability. Finally, we also studied the"/>
 <result pre="to inhibit ZIKV infection by affecting both viral replication and" exact="viral" post="stability. Finally, we also studied the effects of CET"/>
 <result pre="against ZIKV. CET exerts anti-ZIKV activities through the inhibition of" exact="viral" post="production and replication as well as through virucidal activity."/>
 <result pre="Mortal. Wkly. Rep.652016555826820163 6TeixeiraM.G.Costa MdaC.de OliveiraW.K.NunesM.L.RodriguesL.C.The epidemic of Zika virus-related" exact="microcephaly" post="in Brazil: detection, control, etiology, and future scenariosAm. J."/>
 <result pre="activity of pinocembrin against Zika virus replicationAntivir. Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of" exact="congenital" post="Zika disease depend on timing of infection and maternal-fetal"/>
 <result pre="pinocembrin against Zika virus replicationAntivir. Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of congenital Zika" exact="disease" post="depend on timing of infection and maternal-fetal interferon actionCell"/>
 <result pre="Res.1672019132430959074 9ChenJ.LiangY.YiP.XuL.HawkinsH.K.RossiS.L.SoongL.CaiJ.MenonR.SunJ.Outcomes of congenital Zika disease depend on timing of" exact="infection" post="and maternal-fetal interferon actionCell Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika virus infection in"/>
 <result pre="on timing of infection and maternal-fetal interferon actionCell Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika" exact="virus infection" post="in pregnancy: a systematic review of disease course and"/>
 <result pre="timing of infection and maternal-fetal interferon actionCell Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika virus" exact="infection" post="in pregnancy: a systematic review of disease course and"/>
 <result pre="Rep.2120171588159929117563 10ChibuezeE.C.TiradoV.LopesK.D.BalogunO.O.TakemotoY.SwaT.DagvadorjA.NagataC.MorisakiN.MenendezC.OtaE.MoriR.OladapoO.T.Zika virus infection in pregnancy: a systematic review of" exact="disease" post="course and complicationsReprod. Health1420172828241773 11ZammarchiL.StellaG.MantellaA.BartolozziD.TappeD.GuntherS.OestereichL.CadarD.Munoz-FontelaC.BartoloniA.Schmidt-ChanasitJ.Zika virus infections imported to"/>
 <result pre="systematic review of disease course and complicationsReprod. Health1420172828241773 11ZammarchiL.StellaG.MantellaA.BartolozziD.TappeD.GuntherS.OestereichL.CadarD.Munoz-FontelaC.BartoloniA.Schmidt-ChanasitJ.Zika virus" exact="infections" post="imported to Italy: clinical, immunological and virological findings, and"/>
 <result pre="health implicationsJ. Clin. Virol.632015323525600600 12VenturaC.V.MaiaM.Bravo-FilhoV.GoisA.L.BelfortR.Jr.Zika virus in Brazil and macular" exact="atrophy" post="in a child with microcephalyLancet3872016228 13Zika virus infection: global"/>
 <result pre="of cantharidin, cephalotaxine and homoharringtonine on &quot;in vitro&quot; models of" exact="hepatitis" post="B virus (HBV) and bovine viral diarrhoea virus (BVDV)"/>
 <result pre="&quot;in vitro&quot; models of hepatitis B virus (HBV) and bovine" exact="viral" post="diarrhoea virus (BVDV) replicationPlanta Med.73200755255817458779 17Perard-ViretJ.QuteishatL.AlsalimR.RoyerJ.DumasF.Cephalotaxus alkaloidsAlkaloids Chem. Biol.78201720535228838429"/>
 <result pre="and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human" exact="tumor" post="cell linesNaunyn-Schmiedeberg’s Arch. Pharmacol.3672003566712616342 19KaurP.ThiruchelvanM.LeeR.C.ChenH.ChenK.C.NgM.L.ChuJ.J.Inhibition of chikungunya virus replication"/>
 <result pre="hainanensis in human tumor cell linesNaunyn-Schmiedeberg’s Arch. Pharmacol.3672003566712616342 19KaurP.ThiruchelvanM.LeeR.C.ChenH.ChenK.C.NgM.L.ChuJ.J.Inhibition of" exact="chikungunya" post="virus replication by harringtonine, a novel antiviral that suppresses"/>
 <result pre="chikungunya virus replication by harringtonine, a novel antiviral that suppresses" exact="viral" post="protein expressionAntimicrob. Agents Chemother.57201315516723275491 20CaoJ.ForrestJ.C.ZhangX.A screen of the NIH"/>
 <result pre="in vitroJ. Microbiol.572019747930456755 22HoY.J.LiuF.C.YehC.T.YangC.M.LinC.C.LinT.Y.HsiehP.S.HuM.K.GongZ.LuJ.W.Micafungin is a novel anti-viral agent of" exact="chikungunya" post="virus through multiple mechanismsAntivir. Res.159201813414230300716 23HoY.J.LuJ.W.HuangY.L.LaiZ.Z.Palmatine inhibits Zika virus"/>
 <result pre="of chikungunya virus through multiple mechanismsAntivir. Res.159201813414230300716 23HoY.J.LuJ.W.HuangY.L.LaiZ.Z.Palmatine inhibits Zika" exact="virus infection" post="by disrupting virus binding, entry, and stabilityBiochem. Biophys. Res."/>
 <result pre="chikungunya virus through multiple mechanismsAntivir. Res.159201813414230300716 23HoY.J.LuJ.W.HuangY.L.LaiZ.Z.Palmatine inhibits Zika virus" exact="infection" post="by disrupting virus binding, entry, and stabilityBiochem. Biophys. Res."/>
 <result pre="effects of combination treatment using EGCG and suramin against the" exact="chikungunya" post="virusBiochem. Biophys. Res. Commun.491201759560228760340 25AdcockR.S.ChuY.K.GoldenJ.E.ChungD.H.Evaluation of anti-Zika virus activities"/>
 <result pre="J. Biochem.721977323330319998 28JiaK.YuanY.LiuW.LiuL.QinQ.YiM.Identification of inhibitory compounds against Singapore grouper iridovirus" exact="infection" post="by cell viability-based screening assay and droplet digital PCRMar."/>
 <result pre="protein biosynthesisMol. Pharmacol.1119755115191237080 30ZhouD.C.ZittounR.MarieJ.P.Homoharringtonine: an effective new natural product in" exact="cancer" post="chemotherapyBull. Cancer8219959879958745664 Appendix A Supplementary data The following is"/>
</results>
